Inhaled Budesonide for Altitude Illness Prevention
Primary Purpose
Altitude Sickness
Status
Withdrawn
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Budesonide
Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Altitude Sickness
Eligibility Criteria
Inclusion Criteria:
- healthy, altitude naive, 21-40 years old
Exclusion Criteria:
- smokers
- pregnancy
- hx of asthma
- current inhaled steroid use
those with diseases or disorders known to be affected by hypoxia or the drugs used in this study such as
- migraine or other chronic headaches,
- sickle cell trait or disease, or
- diabetes
- history of significant head injury or seizures
- taking any medication (over-the-counter or prescription) or herbal supplements
- a known hypersensitivity reaction to budesonide
- inability to be headache-free when consuming the amount of caffeine in two six ounce cups of coffee or less per day
- exposure to high altitude above 2000m in the previous 1 month or
- those who have been on an airline flight over six hours (Airplane cabins are pressurized to an elevation that can approximate exposure to high altitude)
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Budesonide
Placebo
Arm Description
Will participate in all study activities but will receive budesonide.
Will participate in all study activities but will receive placebo.
Outcomes
Primary Outcome Measures
Changes in Inflammation
Analysis to compare activity in pro-inflammatory pathways and activity in anti-permeability pathways, as measured by serum markers, between budesonide and placebo.
Incidence of Acute Mountain Sickness (AMS)
Comparison of incidence and severity of acute mountain sickness between budesonide and placebo.
Changes in Gene regulation
Comparison of gene regulation involved in acclimatization and altitude illness.
Secondary Outcome Measures
Full Information
NCT ID
NCT02941510
First Posted
October 19, 2016
Last Updated
March 9, 2017
Sponsor
University of Colorado, Denver
1. Study Identification
Unique Protocol Identification Number
NCT02941510
Brief Title
Inhaled Budesonide for Altitude Illness Prevention
Official Title
Inhaled Budesonide for Altitude Illness Prevention
Study Type
Interventional
2. Study Status
Record Verification Date
March 2017
Overall Recruitment Status
Withdrawn
Why Stopped
Stopped prior to enrollment per PI and DSMB decision.
Study Start Date
March 6, 2017 (Actual)
Primary Completion Date
March 6, 2017 (Actual)
Study Completion Date
March 6, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Colorado, Denver
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
A randomized, double-blinded study administering budesonide, a medication to reduce inflammation in the lungs, to healthy volunteers to examine effects on altitude illness prevention by spending 18 hours overnight at 14,000 ft elevation.
Detailed Description
A randomized, double-blinded study will be conducted to validate the results of previous literature on the use of budesonide in the prevention of altitude sickness. It will be conducted using healthy participants overseen by experienced wilderness medicine and altitude researchers from the Altitude Research Center at University of Colorado Denver. Participants will be recruited from the Denver community and prescreened for eligibility via phone. 100 participants, after consenting, will have baseline data and blood collected and will begin budesonide therapy 72 hours prior to being taken from Denver to Pikes Peak, where they will be observed at altitude for 18 hours. Patients will have the opportunity to withdraw consent at any time and will be monitored continuously by physician-researchers. Data collection and blood draws will be performed at specific time points and analyzed for efficacy of budesonide vs. placebo in the incidence of altitude sickness.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Altitude Sickness
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Budesonide
Arm Type
Experimental
Arm Description
Will participate in all study activities but will receive budesonide.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Will participate in all study activities but will receive placebo.
Intervention Type
Drug
Intervention Name(s)
Budesonide
Intervention Description
Budesonide is FDA approved for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). It works by reducing lung inflammation to increase oxygen uptake by the body. The researchers are examining if this medication can prevent altitude sickness.
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Subject(s) will participate in all study activities but will receive placebo.
Primary Outcome Measure Information:
Title
Changes in Inflammation
Description
Analysis to compare activity in pro-inflammatory pathways and activity in anti-permeability pathways, as measured by serum markers, between budesonide and placebo.
Time Frame
During 18 hours at elevation compared to baseline.
Title
Incidence of Acute Mountain Sickness (AMS)
Description
Comparison of incidence and severity of acute mountain sickness between budesonide and placebo.
Time Frame
During 18 hours at elevation compared to baseline.
Title
Changes in Gene regulation
Description
Comparison of gene regulation involved in acclimatization and altitude illness.
Time Frame
During 18 hours at elevation compared to baseline.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
healthy, altitude naive, 21-40 years old
Exclusion Criteria:
smokers
pregnancy
hx of asthma
current inhaled steroid use
those with diseases or disorders known to be affected by hypoxia or the drugs used in this study such as
migraine or other chronic headaches,
sickle cell trait or disease, or
diabetes
history of significant head injury or seizures
taking any medication (over-the-counter or prescription) or herbal supplements
a known hypersensitivity reaction to budesonide
inability to be headache-free when consuming the amount of caffeine in two six ounce cups of coffee or less per day
exposure to high altitude above 2000m in the previous 1 month or
those who have been on an airline flight over six hours (Airplane cabins are pressurized to an elevation that can approximate exposure to high altitude)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ryan Paterson, MD, DiMM
Organizational Affiliation
University of Colorado, Denver
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Inhaled Budesonide for Altitude Illness Prevention
We'll reach out to this number within 24 hrs